Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Sijbesma, Jürgen W. A.
141  Ergebnisse:
Personensuche X
?
1

Caloric restriction reduces proteinuria in male rats with e..:

Sijbesma, J. W. A. ; van Waarde, A. ; Klooster, A....
Physiological Reports.  12 (2024)  5 - p. , 2024
Link: https://doi.org/10.14814..
 
?
2

Hepatic Spheroid Formation on Carbohydrate-Functionalized S..:

Liu, Jie ; Zhang, Ying ; van Dongen, Kim...
Biomacromolecules.  24 (2023)  6 - p. 2447-2458 , 2023
Link: https://doi.org/10.1021/..
 
?
3

Characterization of a novel model for atherosclerosis imagi..:

Sijbesma, Jürgen W. A. ; van Waarde, Aren ; Kristensen, Sebastiaan...
EJNMMI Research.  13 (2023)  1 - p. , 2023
Link: https://doi.org/10.1186/..
 
?
4

Preclinical evaluation of 2-[18F]fluorodeoxysorbitol as a t..:

Braams, Lisanne M. ; Sijbesma, Jürgen W.A. ; Boersma, Hendrikus H....
International Journal of Medical Microbiology.  313 (2023)  3 - p. 151581 , 2023
Link: https://doi.org/10.1016/..
 
?
5

Characterization of a novel model for atherosclerosis imagi..:

Sijbesma, Jürgen W.A ; van Waarde, Aren ; Kristensen, Sebastiaan...
https://research.rug.nl/en/publications/1679ca03-2fde-43bf-a560-0eab1b6ce1ca.  , 2023
Link: https://hdl.handle.net/1..
 
?
6

Preclinical evaluation of 2-[18F]fluorodeoxysorbitol as a t..:

Lisanne M. Braams ; Jürgen W.A. Sijbesma ; Hendrikus H. Boersma...
http://www.sciencedirect.com/science/article/pii/S1438422123000097.  , 2023
Link: https://doi.org/10.1016/..
 
?
7

Preclinical evaluation of 2-[18F]fluorodeoxysorbitol as a t..:

Braams, Lisanne M ; Sijbesma, Jürgen W A ; Boersma, Hendrikus H...
https://research.rug.nl/en/publications/91d81f79-c2b4-41ed-98d8-394ecf86d862.  , 2023
Link: https://hdl.handle.net/1..
 
?
8

Characterization of a novel model for atherosclerosis imagi..:

Sijbesma, Jürgen W. A ; van Waarde, Aren ; Kristensen, Sebastiaan...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10713960/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
9

Characterization of a novel model for atherosclerosis imagi..:

Jürgen W. A. Sijbesma ; Aren van Waarde ; Sebastiaan Kristensen...
https://doi.org/10.1186/s13550-023-01055-5.  , 2023
Link: https://doi.org/10.1186/..
 
?
10

Binding of the Dual-Action Anti-Parkinsonian Drug AG-0029 t..:

Ghazanfari, Nafiseh ; van Waarde, Aren ; Doorduin, Janine...
Molecular Pharmaceutics.  19 (2022)  7 - p. 2287-2298 , 2022
Link: https://doi.org/10.1021/..
 
?
11

Impact of an Adenosine A2A Receptor Agonist and Antagonist ..:

Prasad, Kavya ; de Vries, Erik F. J. ; Sijbesma, Jürgen W. A....
Molecular Pharmaceutics.  19 (2022)  8 - p. 2992-3001 , 2022
Link: https://doi.org/10.1021/..
 
?
12

Pharmacokinetic Modeling of [11C]GSK-189254, PET Tracer Tar..:

Ghazanfari, Nafiseh ; van Waarde, Aren ; Doorduin, Janine...
Molecular Pharmaceutics.  19 (2022)  3 - p. 918-928 , 2022
Link: https://doi.org/10.1021/..
 
?
13

Pharmacokinetic Modeling of [(11)C]GSK-189254, PET Tracer T..:

Ghazanfari, Nafiseh ; van Waarde, Aren ; Doorduin, Janine...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905578/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
14

Binding of the Dual-Action Anti-Parkinsonian Drug AG-0029 t..:

Ghazanfari, Nafiseh ; van Waarde, Aren ; Doorduin, Janine...
https://research.rug.nl/en/publications/b086a6af-eedc-4eb6-b817-0244a9d9697d.  , 2022
Link: https://hdl.handle.net/1..
 
?
15

Binding of the Dual-Action Anti-Parkinsonian Drug AG-0029 t..:

Ghazanfari, Nafiseh ; van Waarde, Aren ; Doorduin, Janine...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257755/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
1-15